PFE (Pfizer, Inc.)
August 4, 2009 by Hot Stocks To Buy · Leave a Comment
PFE (Pfizer, Inc.)
- Entry Price: $16.07
- Risk Level:8
- Profitability Level: 7
- 1year Target Price: $20-$25
Having settled the 1996 Trovan clinical study case with the Kano State government in Nigeria, Pfizer can move forward to other developing drugs. Pfizer Inc (NYSE: PFE), together with Medivation, Inc. (NASDAQ: MDVN) has started the initiation of a Phase 3 trial of the investigational drug Dimebon (Latrepirdine) in patients with Huntington disease. In addition, the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to Dimebon for the treatment of Huntington disease.
On January 26, 2009 Pfizer and Wyeth entered into a definitive merger agreement under which Pfizer will acquire Wyeth in a cash-and-stock transaction. The conglomerate company will create one of the most diversified companies in the global health care industry, with product offerings in numerous growing therapeutic areas, a strong product pipeline, and leading scientific and manufacturing capabilities.
Yahoo analysts estimate growth for the following year to be 13.8%; 3.8% over the industry’s projected growth, making Pfizer a hot stock to buy.
We wish you luck on your investments and as always do your own research prior to purchasing or selling a stock. We make recommendations based on our own research and this site is solely for the purpose of entertainment reading. Thank you for visiting Hot Stocks to Buy.
